fashion -WSS

fashion

author：fashion 2025-09-29 01:34:52 - browse：52532

The U.S. Capitol reflection. -- health coverage from STAT — Nathan Howard/Getty Images

WASHINGTON — Around the country, statehouses from Harrisburg, Pa., to Tallahassee, Fla., are being flooded with tobacco industry lobbyists, according to a new report from the anti-smoking advocacy group Action on Smoking and Health.

There are now at least 950 lobbyists representing cigarette, vape, and snus companies in statehouses around the country, according to the latest edition of the group’s Tobacco Industry Lobbyist and Lobbying Firm Registration Tracker, which was released Thursday. The number of lobbying registrations tied to tobacco companies jumped over 10% from 2023 to 2024.

ASH’s overall tally, which is based on publicly available lobbying registration data, is likely an undercount because several states only require lobbying firms, not individual lobbyists, to register with the state.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Report: NIH

focus

WSS

Anthos stroke drug appears safer than common blood thinner

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Adam's Biotech Scorecard: Do Sarepta's exon

Report: NIH

CRISPR pioneers react to Casgevy, first gene

Insmed lung disease drug hits target in key Phase 3 trial

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

In age of alternative facts, a scholarly course on calling out crap

FDA's Woodcock to retire early next year

United colonoscopy coverage change 'may cost lives,' doctors say

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Duchenne breakthrough therapy leaves behind pioneering families

Heat waves linked to early deliveries, preterm births in new study

The cancer drug shortage isn’t new — and neither are the solutions

Report: NIH

Bright Health sells Medicare Advantage business to Molina

Does good food count as health care? Study aims to find out

focus

David Sabatini, ex

NYU radiologists take on the challenge of expensive MRI machines

Latest bird flu infection made farmworker sicker than earlier cases

Do more moles mean more problems? Not so, says new study

Stigma and the return of syphilis

Childbirth

explore

focus

explore

explore